SciDoc Publishers | Open Access | Science Journals | Media Partners

International Journal of Food Science, Nutrition and Dietetics (IJFS)    IJFS-2326-3350-03-002e

Pros and Cons of Ascorbic Acid (Vitamin C) Use In Cancers

Farid Menaa

1 Founder, President & CEO, Bionanomics Ltda, Sao Paulo, Brazil

*Corresponding Author

Prof. Dr. Farid Menaa,
Oncologist,Founder, President & CEO, Bionanomics Ltda,
Sao Paulo, Brazil

Received: September 24, 2014; Published: October 14, 2014

Citation: Farid Menaa (2014) Pros and Cons of Ascorbic Acid (Vitamin C) Use In Cancers. Int J Food Sci Nutr Diet. 3(3), 1. doi:

Copyright: Farid Menaa © 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

For decades, ascorbic acid ( aka vitamin C), has been popularly prescribed by alternative and complementary health care practitioners and used by individuals or patients with various health conditions, including cancer progression [1], due to its renowned antioxidant property [2], which consists to neutralize free radicals such as superoxide (H2O2) and hydroxyl (OH) radicals, as well as its capacity to protect and repair normal cells that are damaged by chemotherapy or radiation therapy [3]. Surprisingly, the mechanism of anti-tumor effect of ascorbic acid, especially used at high dose, has been proposed to be mediated by generation of H2O2 and secondary metabolite[4].

Interestingly, a number of studies have reported the benefits of ascorbic acid in preventing and treating cancers [5]. Thereby, in some preclinical studies led in-vitro and in-vivo, ascorbic acid induced tumor cells apoptosis and even enhanced the anti-tumor effects of chemotherapy [6-7], acting then as a potentially good therapeutic adjuvant. Conversely, evidence from other studies and randomized trials[8] suggested that ascorbic acid during chemotherapy or radiation therapy may protect tumor cells and reduce the treatment efficacy.

Besides, a meta-analysis published this year and which aimed to associate dietary ascorbic acid supplement intake and survival in breast cancer patients, showed that the relative risk (RR) of breast cancer-specific mortality can be lowered with 100 mg intake per day of ascorbic acid,[9]. However, it is important to point out the fact that the experimental conditions of the studies used in this meta-analysis differed notably in terms of dosage, formulation and administration type and schedule, causing these confounders difficult to control. Besides, it is noteworthy that in sub-analysis of Women’s Health Initiative (WHI) study, dietary intake of ascorbic acid was not associated with a reduction in ovarian cancer risk [10].

Therefore, the challenging issues still concern:

(i) which dose (high or low) and administration setting are really beneficial for a patient suffering from cancer?
(ii) which cancer is prone to ascorbic acid therapy based on efficacy/toxicity risk ratio?
(iii) which are the fully clear molecular mechanisms mediated by ascorbic acid in cancers?;
(iv) which are the benefits or risks of using nano encapsulated ascorbic acid, considering the systemic bioavailability of such compound?;
(v) which are the benefits or risks of combining (nano-)ascorbic acid with (nano-) anti-cancer agents (chemical drugs and/or bio therapeutics)?

In light of these few observations from inconsistent studies, it is difficult to state that ascorbic acid is an anti-cancer agent, and many issues still need to be accurately and promptly addressed first from a holistic point of view before prescribing it in a personalized manner. Ongoing studies certainly provide new interesting insights about ascorbic acid effects on cancers.


  1. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, et al. (2010). Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects PloS one 5(7): e11414
  2. Frei B. (1994) Reactive oxygen species and antioxidant vitamins: mechanisms of action. The American journal of medicine 97:5S-13S.
  3. Nakayama A, Alladin KP, Igbokwe O, White JD. (2011) Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. Cancer investigation 29:655- 67.
  4. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, et al. (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proceedings of the National Academy of Sciences of the United States of America 104:8749-54.
  5. Cameron E, Pauling L. (1976) Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences of the United States of America 73:3685-9.
  6. Drisko JA, Chapman J, Hunter VJ. (2003) The use of antioxidant therapies during chemotherapy. Gynecologic oncology 88:434-9.
  7. Prasad KN, Cole WC, Kumar B, Che Prasad K. (2002) Pros and cons of antioxidant use during radiation therapy. Cancer treatment reviews 28:79-91.
  8. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, et al. (2008). Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Journal of the National Cancer Institute 100:773-83.
  9. Harris HR, Orsini N, Wolk A. (2014) Vitamin C and survival among women with breast cancer: a meta-analysis. European journal of cancer 50:1223-31.
  10. Thomson CA, Neuhouser ML, Shikany JM, Caan BJ, Monk BJ, et al. (2008) The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative Nutrition and cancer 60:710-9.

         Indexed in

pubhub   CGS   indexcoop   j-gate   DOAJ   Google_Scholar_logo

       Total Visitors

SciDoc Counter

Get in Touch

SciDoc Publishers
16192 Coastal Highway
Lewes, Delaware 19958
Tel :+1-(302)-703-1005
Fax :+1-(302)-351-7355

Creative Commons License
SciDoc Publishers is licensed under a Creative Commons Attribution 4.0 International License.